Phathom Historical Income Statement
| PHAT Stock | USD 8.97 0.12 1.32% |
Historical analysis of Phathom Pharmaceuticals income statement accounts such as Total Revenue of 716.1 K, Other Operating Expenses of 129.9 M, Research Development of 71.7 M or Total Operating Expenses of 129.9 M can show how well Phathom Pharmaceuticals performed in making a profits. Evaluating Phathom Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Phathom Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Phathom Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Phathom Pharmaceuticals is a good buy for the upcoming year.
Phathom |
About Phathom Income Statement Analysis
Phathom Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Phathom Pharmaceuticals shareholders. The income statement also shows Phathom investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Phathom Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Phathom Pharmaceuticals. It is also known as Phathom Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Phathom Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Phathom Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Phathom Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Phathom Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phathom Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.At this time, Phathom Pharmaceuticals' Interest Income is comparatively stable compared to the past year. Depreciation And Amortization is likely to gain to about 603.8 K in 2024, whereas Operating Income is likely to drop (175.7 M) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 521K | 620K | 575K | 450.3K | Cost Of Revenue | 521K | 620K | 167K | 158.7K |
Phathom Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Phathom Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Phathom Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (3.1M) | (3.5M) | (6.7M) | (25.2M) | (34.1M) | (32.4M) | |
| Interest Income | 1.1M | 1.1M | 41K | 2.1M | 7.9M | 8.3M | |
| Depreciation And Amortization | (48.5M) | 300K | 521K | 620K | 575K | 603.8K | |
| Interest Expense | 4.2M | 4.6M | 6.8M | 27.3M | 42.0M | 44.1M | |
| Selling General Administrative | 6.9M | 27.5M | 62.7M | 101.0M | 117.9M | 123.8M | |
| Other Operating Expenses | 106.2M | 125.7M | 135.1M | 172.4M | 168.0M | 129.9M | |
| Operating Income | (106.2M) | (125.7M) | (135.1M) | (172.4M) | (167.3M) | (175.7M) | |
| Net Income From Continuing Ops | (255.1M) | (129.1M) | (143.9M) | (197.7M) | (201.6M) | (211.7M) | |
| Ebit | (106.2M) | (124.5M) | (135.1M) | (172.4M) | (159.6M) | (167.6M) | |
| Research Development | 99.3M | 98.1M | 72.3M | 71.4M | 49.9M | 71.7M | |
| Ebitda | (154.7M) | (124.2M) | (134.6M) | (171.8M) | (159.0M) | (167.0M) | |
| Total Operating Expenses | 106.2M | 125.7M | 135.1M | 172.4M | 167.8M | 129.9M | |
| Income Before Tax | (255.1M) | (129.1M) | (143.9M) | (197.7M) | (201.6M) | (211.7M) | |
| Total Other Income Expense Net | (148.9M) | (3.4M) | (8.8M) | (25.3M) | (34.3M) | (36.0M) | |
| Net Income Applicable To Common Shares | (255.1M) | (129.1M) | (143.9M) | (197.7M) | (178.0M) | (186.8M) | |
| Net Income | (209.7M) | (133.3M) | (148.1M) | (223.0M) | (201.6M) | (211.7M) | |
| Income Tax Expense | (45.4M) | 4.3M | 4.2M | 25.3M | 41.8M | 43.9M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.